DR. ASHWANI KUMAR AGARWAL, M.D.
Osteopathic Medicine at Wheatland Rd, Dallas, TX
License number
Texas K3052
Category
Osteopathic Medicine
Type
Medical Oncology
License number
Texas K3052
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
3555 W Wheatland Rd, Dallas, TX 75237
Phone
(972) 709-2580
(972) 283-9387 (Fax)
(972) 997-8000
(972) 437-9605 (Fax)
(972) 283-9387 (Fax)
(972) 997-8000
(972) 437-9605 (Fax)
Professional information
Physician At Texas Oncology
Position:
physician at Texas Oncology
Location:
Dallas/Fort Worth Area
Industry:
Hospital & Health Care
Work:
Texas Oncology
-
physician
Education:
All India Institute of Medical Sciences 1982 - 1984
Ashwani Kumar Agarwal, Dallas TX
Specialties:
Hematologist
Address:
3555 W Wheatland Rd, Dallas, TX 75237
Education:
Armed Forces Medical College - Bachelor of Medicine, Bachelor of Surgery
Board certifications:
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Physician At Texas Oncology
Position:
physician at texas oncology
Location:
Dallas/Fort Worth Area
Industry:
Medical Practice
Work:
texas oncology
-
physician
Dr At Texas Oncology
Position:
dr at texas oncology
Location:
Dallas/Fort Worth Area
Industry:
Medical Practice
Work:
texas oncology
-
dr
Anti-Emetic Substance
US Patent:
2012010, Apr 26, 2012
Filed:
Jun 8, 2011
Appl. No.:
13/156133
Inventors:
Ashwani Agarwal - Dallas TX, US
Ankit Bharat - St. Louis MO, US
Ankit Bharat - St. Louis MO, US
International Classification:
A61K 31/5415, A61P 1/08
US Classification:
5142262, 5142248
Abstract:
The present invention provides a therapeutic solution for effective control of symptoms related to nausea and vomiting. The therapeutic solution is a pharmaceutical composition which combines anti-emetics of different classes. These classes include dopamine receptor antagonists, serotonin receptor antagonists, butyrphenones, and neurokinin receptor antagonists. The combination of different anti-emetics mitigates adverse affects of a single anti-emetic alone while increasing drug efficacy and decreasing cost of administration to the individual patient.